Literature DB >> 1380477

The degree of variability in the amino terminal region of the E2/NS1 protein of hepatitis C virus correlates with responsiveness to interferon therapy in viremic patients.

S Okada1, Y Akahane, H Suzuki, H Okamoto, S Mishiro.   

Abstract

We investigated amino acid heterogeneity in the variable regions of the E2/NS1 viral protein in interferon-responsive and interferon-nonresponsive patients with chronic hepatitis C virus infection. The study assessed whether any particular heterogeneity pattern(s) could be useful in predicting responsiveness to interferon treatment. The nucleic acid sequences of the hepatitis C virus genome were analyzed from six patients with chronic hepatitis treated with an interferon-beta, three of whom did not respond to the therapy and another three who showed remarkable improvement in the serum levels of liver enzymes and hepatitis C virus RNA after 6 mo. The complementary DNA clones propagated from each of the nonresponders showed significant diversity of both nucleotide and amino acid sequence, especially at the hypervariable region 1 within the putative E2/NS1 gene of the virus, suggesting that these patients were infected with a large heterogeneous pool of hepatitis C virus variants. In contrast, the responders showed little or no diversity in the sequence of the complementary DNA clones, suggesting that they were infected with one or a small population of viral genotypes containing significantly less variability in the E2/NS1 hypervariable region 1. These results suggested that a large variable population of hepatitis C virus genotypes is implicated in patients who are nonresponders to interferon treatment. In addition, a significant change in the hepatitis C virus genotype population was observed in nonresponders after interferon treatment. This may reflect a differential viral sensitivity to interferon, selective immune pressure by the host or both.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1380477     DOI: 10.1002/hep.1840160302

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  52 in total

1.  The Effect Of Long Term and High Dose Interferon Treatment In Chronic Hepatitis C.

Authors:  Gábor Horváth; Gyula Stotz; Gyula Tolvaj; Henrik Osztrogonácz; Károly Dávid
Journal:  Pathol Oncol Res       Date:  1996       Impact factor: 3.201

2.  Clinical guidelines on the management of hepatitis C.

Authors:  J C Booth; J O'Grady; J Neuberger
Journal:  Gut       Date:  2001-07       Impact factor: 23.059

3.  Combined therapy with interferon and ribavirin in chronic hepatitis C does not affect serum quasispecies diversity.

Authors:  S Sookoian; G Castaño; B Frider; J Cello; R Campos; D Flichman
Journal:  Dig Dis Sci       Date:  2001-05       Impact factor: 3.199

4.  Hepatitis C virus envelope proteins bind lactoferrin.

Authors:  M Yi; S Kaneko; D Y Yu; S Murakami
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

5.  Significance of pretreatment analysis of hepatitis C virus genotype 1b hypervariable region 1 sequences to predict antiviral outcome.

Authors:  Catherine Gaudy; Alain Moreau; Pascal Veillon; Stephanie Temoin; Francoise Lunel; Alain Goudeau
Journal:  J Clin Microbiol       Date:  2003-08       Impact factor: 5.948

6.  Quasispecies as predictive response factors for antiviral treatment in patients with chronic hepatitis C.

Authors:  Javier Salmerón; Paloma Muñoz De Rueda; Angela Ruiz-Extremera; Jorge Casado; Carlos Huertas; Maria Del Carmen Bernal; Luis Rodríguez; Angel Palacios
Journal:  Dig Dis Sci       Date:  2006-05       Impact factor: 3.199

Review 7.  Viral determinants of resistance to treatment in patients with hepatitis C.

Authors:  Anette Wohnsland; Wolf Peter Hofmann; Christoph Sarrazin
Journal:  Clin Microbiol Rev       Date:  2007-01       Impact factor: 26.132

8.  Long-term persistence of infection in chimpanzees inoculated with an infectious hepatitis C virus clone is associated with a decrease in the viral amino acid substitution rate and low levels of heterogeneity.

Authors:  Javier Fernandez; Deborah Taylor; Duncan R Morhardt; Kathleen Mihalik; Montserrat Puig; Charles M Rice; Stephen M Feinstone; Marian E Major
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

9.  Effectiveness of leukocyte interferon-alpha treatment in patients with chronic hepatitis C not responsive to recombinant interferon.

Authors:  G Scotto; M Grimaldi
Journal:  Dig Dis Sci       Date:  1998-10       Impact factor: 3.199

10.  Structural analysis of hepatitis C RNA genome using DNA microarrays.

Authors:  María Martell; Carlos Briones; Aránzazu de Vicente; María Piron; Juan I Esteban; Rafael Esteban; Jaime Guardia; Jordi Gómez
Journal:  Nucleic Acids Res       Date:  2004-06-24       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.